Published in Nat Rev Nephrol on July 16, 2013
Omics databases on kidney disease: where they can be found and how to benefit from them. Clin Kidney J (2016) 0.87
Insights into kidney diseases from genome-wide association studies. Nat Rev Nephrol (2016) 0.79
Biomarkers for Refractory Lupus Nephritis: A Microarray Study of Kidney Tissue. Int J Mol Sci (2015) 0.78
Risk alleles for IgA nephropathy-associated SNPs conferred completely opposite effects to idiopathic membranous nephropathy in Chinese Han. Immunol Res (2017) 0.75
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science (2010) 16.00
M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med (2009) 11.81
MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet (2008) 9.50
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet (2008) 9.00
The microRNA spectrum in 12 body fluids. Clin Chem (2010) 6.82
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med (2011) 6.34
APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol (2011) 4.80
The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A (1982) 4.65
Focal segmental glomerulosclerosis. N Engl J Med (2011) 3.77
Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet (2009) 3.20
Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet (2011) 3.15
Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol (2011) 3.05
Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol (2011) 2.72
MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med (2011) 2.65
Quantitative gene expression analysis in renal biopsies: a novel protocol for a high-throughput multicenter application. Kidney Int (2002) 2.34
Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol (2003) 2.27
COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest (2011) 2.21
Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int (2006) 2.06
Genetic kidney diseases. Lancet (2010) 2.00
Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol (2003) 1.97
A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nat Med (2012) 1.83
A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet (2011) 1.77
MicroRNAs and their role in progressive kidney diseases. Clin J Am Soc Nephrol (2009) 1.77
Current burden and probable increasing incidence of ESRD in China. Clin Nephrol (2010) 1.74
Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol (2012) 1.73
Genetic variation in APOL1 associates with younger age at hemodialysis initiation. J Am Soc Nephrol (2011) 1.70
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int (2013) 1.69
HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol (2010) 1.64
Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int (2005) 1.63
INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. N Engl J Med (2011) 1.53
Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int (2010) 1.46
Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis (2000) 1.43
Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol (2012) 1.41
Mapping a locus for susceptibility to HIV-1-associated nephropathy to mouse chromosome 3. Proc Natl Acad Sci U S A (2004) 1.38
Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes (2012) 1.38
Genetics, clinical and pathological features of glomerulonephritis associated with mutations of nonmuscle myosin IIA (Fechtner syndrome). Am J Kidney Dis (2003) 1.36
Pathogenesis of IgA nephropathy. Nat Rev Nephrol (2012) 1.22
Exome sequencing identified MYO1E and NEIL1 as candidate genes for human autosomal recessive steroid-resistant nephrotic syndrome. Kidney Int (2011) 1.22
Review: The role of microRNAs in kidney disease. Nephrology (Carlton) (2010) 1.22
Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. Dis Markers (2011) 1.21
Molecular genetic analysis of podocyte genes in focal segmental glomerulosclerosis--a review. Eur J Pediatr (2009) 1.19
A molecular profile of focal segmental glomerulosclerosis from formalin-fixed, paraffin-embedded tissue. Am J Pathol (2010) 1.18
Role of systems pharmacology in understanding drug adverse events. Wiley Interdiscip Rev Syst Biol Med (2010) 1.16
Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis Markers (2010) 1.16
A systems view of genetics in chronic kidney disease. Kidney Int (2011) 1.09
APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis. PLoS One (2012) 1.08
Systems biology of kidney diseases. Kidney Int (2011) 1.05
A molecular signature of proteinuria in glomerulonephritis. PLoS One (2010) 1.03
Childhood nephrotic syndrome--current and future therapies. Nat Rev Nephrol (2012) 1.02
Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics (2008) 1.02
Establishment of a 2-D human urinary proteomic map in IgA nephropathy. Proteomics (2006) 1.00
Systems pathology: a paradigm shift in the practice of diagnostic and predictive pathology. Cancer (2009) 1.00
Altered modulation of WNT-beta-catenin and PI3K/Akt pathways in IgA nephropathy. Kidney Int (2010) 0.97
Circulating anti-PLA2R autoantibodies to monitor immunological activity in membranous nephropathy. J Am Soc Nephrol (2011) 0.96
Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy. Anal Bioanal Chem (2012) 0.94
Microarray and bioinformatics analysis of gene expression in experimental membranous nephropathy. Nephron Exp Nephrol (2009) 0.93
Metabolomics as an extension of proteomic analysis: study of acute kidney injury. Semin Nephrol (2007) 0.92
Serial changes in urinary proteome profile of membranous nephropathy: implications for pathophysiology and biomarker discovery. J Proteome Res (2006) 0.92
Gene expression profiles of circulating leukocytes correlate with renal disease activity in IgA nephropathy. Kidney Int (2004) 0.91
Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes. Kidney Int Suppl (1997) 0.90
Biomarkers of diabetic nephropathy, the present and the future. Curr Diabetes Rev (2012) 0.89
Metabolomics: a complementary tool in renal transplantation. Contrib Nephrol (2008) 0.88
Autophagy can repair endoplasmic reticulum stress damage of the passive Heymann nephritis model as revealed by proteomics analysis. J Proteomics (2012) 0.88
Detection of microRNAs in dried serum blots. Anal Biochem (2010) 0.88
Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase. J Am Soc Nephrol (2013) 0.87
Genome-wide association study identifies TNFSF13 as a susceptibility gene for IgA in a South Chinese population in smokers. Immunogenetics (2012) 0.87
Perspectives on systems biology applications in diabetic kidney disease. J Cardiovasc Transl Res (2012) 0.84
Quantitative mRNA expression analysis in kidney glomeruli using microdissection techniques. Histol Histopathol (2011) 0.84
Biomarker discovery in glomerular diseases using urinary proteomics. Proteomics Clin Appl (2008) 0.83
Glomerulosclerosis in mice transgenic for human insulin-like growth factor-binding protein-1. Kidney Int (2000) 0.81
Absence of increased alpha1-microglobulin in IgA nephropathy proteinuria. Mol Cell Proteomics (2007) 0.81
Systematic variations associated with renal disease uncovered by parallel metabolomics of urine and serum. BMC Syst Biol (2012) 0.81
Proteomics and systems biology for understanding diabetic nephropathy. J Cardiovasc Transl Res (2012) 0.80
Urinary proteomics in the assessment of chronic kidney disease. Curr Opin Nephrol Hypertens (2011) 0.80
Urinary proteome analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry with magnetic beads for identifying the pathologic presentation of clinical early IgA nephropathy. J Biomed Nanotechnol (2012) 0.76
Insulin-like growth factor binding protein-1 levels are increased in patients with IgA nephropathy. Biochem Biophys Res Commun (2010) 0.76
Urotensin 2 and retinoic acid receptor alpha (RARA) gene expression in IgA nephropathy. Ann Acad Med Singapore (2010) 0.75
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet (2011) 3.15
Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int (2004) 2.44
Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol (2008) 1.98
Role of the retinoic acid receptor-α in HIV-associated nephropathy. Kidney Int (2010) 1.89
A systems approach identifies HIPK2 as a key regulator of kidney fibrosis. Nat Med (2012) 1.83
Etiology and clinical characteristics of membranous nephropathy in Chinese patients. Am J Kidney Dis (2008) 1.80
A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy. Nat Genet (2011) 1.77
Krüppel-like factor 6 regulates mitochondrial function in the kidney. J Clin Invest (2015) 1.72
Reduction of Stat3 activity attenuates HIV-induced kidney injury. J Am Soc Nephrol (2009) 1.70
Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem (2012) 1.66
Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol (2008) 1.56
A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult chinese patients. Am J Kidney Dis (2012) 1.32
Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor. Proc Natl Acad Sci U S A (2006) 1.32
Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: a cross sectional study. PLoS One (2012) 1.31
Rhein improves renal lesion and ameliorates dyslipidemia in db/db mice with diabetic nephropathy. Planta Med (2009) 1.30
De novo expression of podocyte proteins in parietal epithelial cells in experimental aging nephropathy. Am J Physiol Renal Physiol (2011) 1.28
Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One (2011) 1.24
Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol (2008) 1.22
Kruppel-like factor 15 (KLF15) is a key regulator of podocyte differentiation. J Biol Chem (2012) 1.21
Retinoids augment the expression of podocyte proteins by glomerular parietal epithelial cells in experimental glomerular disease. Nephron Exp Nephrol (2012) 1.17
Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int (2008) 1.15
Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. Kidney Int (2009) 1.15
Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS. Am J Physiol Renal Physiol (2013) 1.13
Signaling in regulation of podocyte phenotypes. Nephron Physiol (2009) 1.13
Obesity-related glomerulopathy in China: a case series of 90 patients. Am J Kidney Dis (2008) 1.09
HIV-associated nephropathy: pathogenesis. Curr Opin Nephrol Hypertens (2011) 1.07
Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol (2008) 1.07
Podocyte lesions in patients with obesity-related glomerulopathy. Am J Kidney Dis (2006) 1.06
Molecular targets for treatment of kidney fibrosis. J Mol Med (Berl) (2012) 1.06
Systems biology of kidney diseases. Kidney Int (2011) 1.05
Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms' tumor-1 protein used as a podocyte marker. Diabetes Res Clin Pract (2009) 1.02
Expression of HIV transgene aggravates kidney injury in diabetic mice. Kidney Int (2013) 1.00
Therapeutic use of traditional Chinese herbal medications for chronic kidney diseases. Kidney Int (2013) 1.00
Atorvastatin in pulmonary arterial hypertension (APATH) study. Eur Respir J (2012) 0.98
Mercury-induced membranous nephropathy: clinical and pathological features. Clin J Am Soc Nephrol (2010) 0.97
Tumour induction in rats following exposure to short-term high dose aristolochic acid I. Mutagenesis (2005) 0.97
Validation of the Oxford classification of IgA nephropathy for pediatric patients from China. BMC Nephrol (2012) 0.97
JAK/STAT signaling in renal diseases. Kidney Int (2010) 0.95
HIV-1 viral protein r induces ERK and caspase-8-dependent apoptosis in renal tubular epithelial cells. AIDS (2010) 0.92
Kidney failure: aims for the next 10 years and barriers to success. Lancet (2013) 0.91
Up-regulation of the homophilic adhesion molecule sidekick-1 in podocytes contributes to glomerulosclerosis. J Biol Chem (2010) 0.91
Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int (2010) 0.91
Roflumilast enhances the renal protective effects of retinoids in an HIV-1 transgenic mouse model of rapidly progressive renal failure. Kidney Int (2012) 0.91
Podocyte-specific deletion of signal transducer and activator of transcription 3 attenuates nephrotoxic serum-induced glomerulonephritis. Kidney Int (2013) 0.90
Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis. J Clin Invest (2014) 0.89
Prevalence and clinical characteristics of sleep apnea in Chinese patients with heart failure. Int J Cardiol (2006) 0.89
Clinical features and renal outcome in lupus patients with diffuse crescentic glomerulonephritis. Rheumatol Int (2009) 0.88
Deletion of podocyte STAT3 mitigates the entire spectrum of HIV-1-associated nephropathy. AIDS (2013) 0.88
Interconnected network motifs control podocyte morphology and kidney function. Sci Signal (2014) 0.87
Podocyte-specific RAP1GAP expression contributes to focal segmental glomerulosclerosis-associated glomerular injury. J Clin Invest (2014) 0.87
Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase. J Am Soc Nephrol (2013) 0.87
The glomerular filtration barrier: components and crosstalk. Int J Nephrol (2012) 0.87
Protein kinase target discovery from genome-wide messenger RNA expression profiling. Mt Sinai J Med (2010) 0.87
Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China. BMC Nephrol (2013) 0.86
Study the oxidative injury of yeast cells by NADH autofluorescence. Spectrochim Acta A Mol Biomol Spectrosc (2006) 0.86
Renal biopsy in type 2 diabetes: timing of complications and evaluating of safety in Chinese patients. Nephrology (Carlton) (2011) 0.86
BnWRI1 coordinates fatty acid biosynthesis and photosynthesis pathways during oil accumulation in rapeseed. J Integr Plant Biol (2014) 0.86
Inguinal and subinguinal micro-varicocelectomy, the optimal surgical management of varicocele: a meta-analysis. Asian J Androl (2015) 0.85
Role of podocyte injury in IgA nephropathy. Contrib Nephrol (2013) 0.84
The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease. Clin Cardiol (2011) 0.84
Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. J Nephrol (2015) 0.84
Long-term outcome and prognostic factors of idiopathic membranous nephropathy in the Chinese population. Clin Nephrol (2013) 0.84
The clinical course and long-term outcome of primary focal segmental glomerulosclerosis in Chinese adults. Clin Nephrol (2013) 0.84
Recurrent or de novo IgA nephropathy with crescent formation after renal transplantation. Ren Fail (2008) 0.83
Transient acidosis during early reperfusion attenuates myocardium ischemia reperfusion injury via PI3k-Akt-eNOS signaling pathway. Oxid Med Cell Longev (2013) 0.83
Overview of lupus nephritis management guidelines and perspective from Asia. Int J Rheum Dis (2013) 0.83
Inhibition of mycophenolic acid on NF-kappaB activity in human endothelial cells. Acta Pharmacol Sin (2002) 0.83
Malignant hypertension in patients with idiopathic IgA nephropathy. Kidney Blood Press Res (2005) 0.83
Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology (Carlton) (2014) 0.83
The ratio of (18)F-FDG activity uptake between the right and left ventricle in patients with pulmonary hypertension correlates with the right ventricular function. Clin Nucl Med (2014) 0.82
Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. Cardiovasc Ther (2010) 0.82
Diabetic nephropathy in a nonobese mouse model of type 2 diabetes mellitus. Am J Physiol Renal Physiol (2014) 0.82
Challenge in pathologic diagnosis of Alport syndrome: evidence from correction of previous misdiagnosis. Orphanet J Rare Dis (2012) 0.82
Oral sildenafil therapy for Chinese patients with pulmonary arterial hypertension: a multicenter study. J Clin Pharmacol (2011) 0.81
Acute responses to inhalation of Iloprost in patients with pulmonary hypertension. Chin Med J (Engl) (2012) 0.81
Effects of continuous positive airway pressure on blood pressure and daytime sleepiness in obstructive sleep apnea patients with coronary heart diseases under optimal medications. Sleep Breath (2011) 0.81
The relationship between obesity and diabetic nephropathy in China. BMC Nephrol (2013) 0.81
Recurrent Proliferative Glomerulonephritis With Monoclonal IgG Deposits After a Renal Transplant Which Was Insensitive to Pulse Therapy Remitted by Double Filtration Plasmapheresis. Exp Clin Transplant (2014) 0.80
Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients. Nephrol Dial Transplant (2006) 0.80
Results of selective hip arthroplasty revision in isolated acetabular failure. J Surg Res (2009) 0.80
An aggressive systematic strategy for acute respiratory distress syndrome caused by severe pneumonia after renal transplantation. Transpl Int (2006) 0.80
Evaluation of metabolic risk marker in obesity-related glomerulopathy. J Ren Nutr (2010) 0.80
Predictive value of D-dimer test for recurrent venous thromboembolism at hospital discharge in patients with acute pulmonary embolism. J Thromb Thrombolysis (2011) 0.80
Inhibition of vascular endothelial growth factor expression and production by triptolide. Planta Med (2002) 0.80
Clinicopathological and genetic characteristics in Chinese patients with lipoprotein glomerulopathy. J Nephrol (2008) 0.80
Effects of nasal continuous positive airway pressure treatment on insulin resistance and ghrelin levels in non-diabetic apnoeic patients with coronary heart disease. Chin Med J (Engl) (2013) 0.79
[Correlation among expression of E-cadherin, beta-catenin, and cyclin D1 in breast cancers]. Ai Zheng (2004) 0.79